DIPROSONE LOTION

Land: Kanada

Tungumál: enska

Heimild: Health Canada

Virkt innihaldsefni:

BETAMETHASONE (BETAMETHASONE DIPROPIONATE)

Fáanlegur frá:

ORGANON CANADA INC.

ATC númer:

D07AC01

INN (Alþjóðlegt nafn):

BETAMETHASONE

Skammtar:

0.05%

Lyfjaform:

LOTION

Samsetning:

BETAMETHASONE (BETAMETHASONE DIPROPIONATE) 0.05%

Stjórnsýsluleið:

TOPICAL

Einingar í pakka:

15G/50G

Gerð lyfseðils:

Prescription

Lækningarsvæði:

ANTI-INFLAMMATORY AGENTS

Vörulýsing:

Active ingredient group (AIG) number: 0106299002; AHFS:

Leyfisstaða:

APPROVED

Leyfisdagur:

2011-02-08

Vara einkenni

1
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
DIPROSONE
®
BETAMETHASONE DIPROPIONATE CREAM, ORGANON STANDARD,
0.05% W/W BETAMETHASONE (AS DIPROPIONATE)
BETAMETHASONE DIPROPIONATE OINTMENT, ORGANON STANDARD,
0.05% W/W BETAMETHASONE (AS DIPROPIONATE)
BETAMETHASONE DIPROPIONATE LOTION, USP,
0.05% W/W BETAMETHASONE (AS DIPROPIONATE)
Topical Corticosteroid
ORGANON CANADA INC.
16766 route Transcanadienne
Kirkland, Quebec
H9H 4M7
www.organon.ca
Date of Initial Approval:
NOV 07, 1974
Date of Revision:
April 7, 2021
Submission Control No.: 249884
2
TABLE OF CONTENTS
TABLE OF CONTENTS
..............................................................................................................2
PART I: HEALTH PROFESSIONAL INFORMATION
..........................................................3
1
INDICATIONS
..................................................................................................................3
1.1
Pediatrics
....................................................................................................................3
1.2
Geriatrics
....................................................................................................................3
2
CONTRAINDICATIONS
.................................................................................................3
3
DOSAGE AND ADMINISTRATION
.............................................................................3
3.1
Dosing Considerations
...............................................................................................3
3.2
Administration
...........................................................................................................4
4
MISSED DOSE
..................................................................................................................4
5
OVERDOSAGE
.................................................................................................................4
6
DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING ................4
7
WARNINGS AND PRECAUTIONS
.........